Yang Song

Statistics

Publications

Citations

320

H-Index

Active since

2007

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Yang Song is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in oncology, cancer pharmacology, and mtor inhibitor therapy.

Publications per year

2007–2014

Publications

The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial

Anders Bonde Jensen, Christopher Wynne, Guillermo Ramírez et al. · Clinical Breast Cancer · 2010 · 145 citations

Medicine, Oncology, Pharmacotherapy +14

A method for testing a prespecified subgroup in clinical trials

Yang Song · Statistics in Medicine · 2007 · 108 citations

Public Health, Biostatistics, Clinical Epidemiology +16

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

Serena Di Cosimo, Sriram Sathyanarayanan, Johanna C. Bendell et al. · Clinical Cancer Research · 2014 · 56 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.

Jean‐Yves Blay, Sant P. Chawla, Isabelle Ray‐Coquard et al. · Journal of Clinical Oncology · 2012 · 11 citations

Medicine, Oncology, Pharmacology +17

1–4 of 4